The Smartest Investors Club
  • Business
  • Politics
  • Investing
  • World
  • Business
  • Politics
  • Investing
  • World

The Smartest Investors Club

Business

Biden administration to lower costs for 64 drugs through inflation penalties on drugmakers

by June 28, 2024
June 28, 2024
Biden administration to lower costs for 64 drugs through inflation penalties on drugmakers

The Biden administration on Wednesday said it will impose inflation penalties on 64 prescription drugs for the third quarter of this year, lowering costs for certain older Americans enrolled in Medicare. 

President Joe Biden has made lowering U.S. drug prices a key pillar of his health-care agenda and reelection platform for 2024. A provision of Biden’s Inflation Reduction Act requires drugmakers to pay rebates to Medicare, the federal health program for Americans over age 65, if they hike the price of a medication faster than the rate of inflation. 

It is separate from another provision under the law that allows Medicare to negotiate lower prescription drug prices with manufacturers. On average, Americans pay two to three times more than patients in other developed nations for prescription drugs, according to the Biden administration.

Some patients will pay a lower coinsurance rate for the 64 drugs covered under Wednesday’s announcement, which fall under Medicare Part B, for the period from July 1 to Sept. 30 “since each drug company raised prices faster than the rate of inflation,” according to a release from the administration.

Some Medicare Part B patients may save as much as $4,593 per day if they use those drugs during the quarter, the release added.  

More than 750,000 Medicare patients use the drugs each year, according to the release. The medications treat conditions such as cancer, certain infections and a bone disease called osteoporosis.

“Without the Inflation Reduction Act, seniors were completely exposed to Big Pharma’s price hikes. Not anymore,” Neera Tanden, White House domestic policy advisor, said in the release.

The Centers for Medicare & Medicaid Services plans to send the first invoices to drugmakers in 2025 for the rebates owed to the program.

In December, Biden released a list of 48 prescription drugs that would be subject to inflation penalties during the first quarter of 2024.

This post appeared first on NBC NEWS
0
FacebookTwitterGoogle +Pinterest
previous post
Option to Acquire Baga Gold Project, Cote d’Ivoire
next post
NFL hit with $4.8 billion in damages over ‘Sunday Ticket’ antitrust case

You may also like

And they’re off! On the sidelines of a...

OpenAI closes funding at $157 billion valuation as...

Over 1.5 million dehumidifiers recalled due to fire...

How Trump could spare Biden’s renewable energy credits...

Target sales ebb after Pride month shopper backlash;...

Walgreens plans store closures as CEO says consumers...

Toyota’s credit business is fined $60M for saddling...

A year after Silicon Valley Bank failed, another...

The great American jobs machine keeps revving in...

Tesla reports 336,000 vehicle deliveries in first quarter,...

    Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Latest

    • Athena Gold Provides Option on Excelsior Springs and Kicks off 2025 Field...

    • Challenges posed by Trump and Putin push UK to adopt new NATO first defense policy

    • Lost dog returns home after swimming to island in 100-mile trip

    • Halcones Precious Metals Provides Update on Polaris Gold Project, Antofagasta Region Chile

    • Charbone Hydrogene Annonce un Financement de Reglements de Dettes par Emission d’Unites pour un Montant Total de 1,3M$

    Categories

    • Business (1,674)
    • Investing (5,020)
    • Politics (7,877)
    • World (6,385)
    • Terms & Conditions
    • Privacy Policy
    • About us

    Disclaimer: thesmartestinvestorsclub.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2024 thesmartestinvestorsclub.com | All Rights Reserved


    Back To Top